Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791

Drugs in R and D

Volumn 8, Issue 2, 2007, Pages 113-119

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DIDANOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; MOZOBIL; PLERIXAFOR; SDZ SID 791; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; BLOATING; BLOOD DISEASE; CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LEUKEMIA; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HEMATOLOGIC DISEASES; HETEROCYCLIC COMPOUNDS; MICE; NEOPLASMS; RATS; RECEPTORS, CXCR4; STEM CELLS; VIRUS DISEASES;

EID: 33847368108     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708020-00006     Document Type: Review

References (28)

1. Genzyme Corporation, AnorMED Inc. Genzyme Completes Tender Offer for Outstanding Shares of AnorMED. Media Release: 7 Nov 2006. Available from URL: http://www.genzyme.com
2. Evotec OAI AG. Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100. Media Release: 16 Feb 2005. Available from URL: http://www.evotecoai.com
3. AnorMED. AnorMED provides outlook for fiscal 2007. Media Release: 13 Jun 2006. Available from URL: http://www.anormed.com
4. Millennium Pharmaceuticals Inc. Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date. Media Release: 27 Sep 2006. Available from URL: http://www.millennium.com
5. AnorMED Inc. AMD-3100 granted orphan drug designation for stem cell transplant in cancer patients. Media Release: 14 Jul 2003. Available from URL: http://www.anormed.com
6. AnorMED Inc. AnorMED to Seek Conditional Marketing Authorization in Europe for MOZOBIL(TM), a New Stem Cell Mobilizer. Media Release: 18 Oct 2005. Available from URL: http://www.anormed.com
7. AnorMED Inc. AnorMED reports fiscal 2007 first quarter results and upcoming milestones. Media Release: 27 Jul 2006. Available from URL: http://www.anormed.com
8. AnorMED Inc. AnorMED expands AMD3100 stem cell transplant program in cancer patients to include Canada and the European Union. Media Release: 4 Nov 2004. Available from URL: http://www.anormed.com
9. AnorMED Inc. AnorMED initiates fifth Phase II trial in cancer patients for new stem cell transplantation drug candidate. Media Release: 1 Apr 2004. Available from URL: http://www.anormed.com
10. AnorMED Inc. AnorMED evaluates new stem cell transplantation drug candidate as single agent in multiple myeloma patients and as combination regimen in patients with Hodgkin?s disease. Media Release: 01 Dec 2004. Available from URL: http://www.anormed.com
11. AnorMED Inc. Medical journal, Blood, reports new stem cell mobilizer improves cancer patient chances for stem cell transplantation. Media Release: 6 Sep 2005. Available from URL: http://www.anormed.com
12. AnorMED. AnorMED initiates Phase I trial in cancer patients to evaluate safety of AMD-3100 for stem cell transplant. Media Release: 6 Sep 2002. Available from URL: http://www.anormed.com
13. Devine S, flomenberg N, Vesole D, et al. Safety and effect on WBC count and CD34+ cell mobilisation following administration of AMD3100 to patients with multiple myeloma or non Hodgkins lymphoma. 8th Congress of the European Society of Hematology Meeting: abstr. 1004, 12 Jun 2003. Available from: URL: http://www.eurocongress.com/eha2003
14. SDZ SID 791 (JM 3100): a mechanistically unique anti-HIV agent with potent antiviral activity in vitro and in vivo. 10th International Conference on AIDS 1: 35, 1994
15. Lack NA, Dale DC, Calandra G, et al. A pharmacokinetic/pharmacodynamic profile of the CXCR4 antagonist AMD3100 for the mobilisation of hematopoietic progenitor cells. Blood 102: 115, No. 11, Part 1, 16 Nov 2003
16. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy 44: 1667-1673, Jun 2000
17. AnorMED Inc. AnorMED announces AMD-3100 mobilizes stem cells. Media Release: [2 pages], 7 Nov 2001. Available from: URL: http://www.anormed.com
18. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilisation of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. Journal of Clinical Oncology 22: 1095-1102, No. 6, 15 Mar 2004
19. AnorMED Inc. Abstracts on new stem cell transplantation drug candidate accepted for presentation at the American Society of Hematology conference. Media Release: 4 Nov 2003. Available from URL: http://www.anormed.com
20. Iwakura A, Yamaguchi J, Luedemann C, et al. AMD-3100, a CXCR4 antagonist, augemnts incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. Blood 100: 293-294, Part 1, 16 Nov 2002
21. Datema R, Rabin L, Hincenbergs M, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrobial Agents and Chemotherapy 40: 750-754, Mar 1996
22. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Medicine 4: 72-77, Jan 1998
23. Blanco J, Barretina J, Henson G, et al. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrobial Agents and Chemotherapy 44: 51-56, Jan 2000
24. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial Agents and Chemotherapy 38: 668-674, Apr 1994
25. Esté JA, De Vreese K, Witvrouw M. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Research 29: 297-307, No. 2-3, Mar 1996
26. Este JA, Schols D, Cabrera C. Inhibition of HIV-1 replication by the bicyclam AMD3100, a CXCR4 antagonist. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 255, 28 Sep 1997
27. AnorMED Inc. AnorMED announces new stem cell transplantation drug candidate addresses unmet medical need in cancer patients. Media Release: 7 Dec 2003. Available from URL: http://www.anormed.com
28. Schols D, Claes S, De Clercq E, et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. 9th Conference on Retroviruses and Opportunistic Infections: abstr. 2, 24 Feb 2002